Topical Aprepitant (HT-001): A Novel Therapy for Epidermal Growth Factor Receptor Inhibitor-Associated Papulopustular Eruptions.

IF 1.5 4区医学 Q3 DERMATOLOGY

Journal of Drugs in Dermatology Pub Date : 2024-09-01 DOI:10.36849/JDD.8617

Nikita Menta, Savanna I Vidal, Adam Friedman

引用次数: 0

Abstract

Papulopustular eruptions are the most common dermatologic side effect of epidermal growth factor receptor inhibitor (EGFRI) therapy. Topical corticosteroids and oral tetracyclines are frequently used to manage these eruptions, though these treatments are limited by their adverse effects and efficacy. Results from preclinical studies suggest a role for topical aprepitant (HT-001) in the treatment of EGFRI-induced skin toxicities. Herein a case of EGFRI-induced papulopustular eruption with rapid treatment response to topical aprepitant (HT-001) 2% cream is described and the literature reviewed. J Drugs Dermatol. 2024;23(9):e173-e174. doi:10.36849/JDD.8617.

查看原文本刊更多论文

局部阿瑞匹坦（HT-001）：表皮生长因子受体抑制剂相关丘疹脓疱病的新型疗法。

丘疹性脓疱是表皮生长因子受体抑制剂（EGFRI）疗法最常见的皮肤科副作用。外用皮质类固醇激素和口服四环素类药物经常被用于控制这些疹子，但这些疗法的不良反应和疗效有限。临床前研究结果表明，外用阿瑞匹坦（HT-001）可用于治疗表皮生长因子受体诱导的皮肤毒性。本文描述了一例表皮生长因子受体（EGFRI）诱发的丘疹脓疱病，患者对外用阿普瑞坦（HT-001）2%乳膏治疗反应迅速，并回顾了相关文献。J Drugs Dermatol.2024;23(9):e173-e174. doi:10.36849/JDD.8617.

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Drugs in Dermatology DERMATOLOGY-

CiteScore

2.20

自引率

13.30%

发文量

289

审稿时长

3-6 weeks

期刊介绍： The Journal of Drugs in Dermatology (JDD) is a peer-reviewed publication indexed with MEDLINE®/PubMed® that was founded by the renowned Dr. Perry Robins MD. Founded in 2002, it offers one of the fastest routes to disseminate dermatologic information and is considered the fastest growing publication in dermatology. We present original articles, award-winning case reports, and timely features pertaining to new methods, techniques, drug therapy, and devices in dermatology that provide readers with peer reviewed content of the utmost quality. Our high standards of content are maintained through a balanced, peer-review process. Articles are reviewed by an International Editorial Board of over 160 renowned experts.